Site-specific and overall cancer risk for men and women with PID
| Cancer site . | O . | E . | SIR (95% CI) . |
|---|---|---|---|
| Male, n = 604 | |||
| All malignant neoplasms† | 23 | 14.0 | 1.64 (1.04-2.46)* |
| NHL | 8 | 0.87 | 9.22 (3.98-18.2)* |
| Leukemia | 2 | 0.35 | 5.77 (0.70-20.9) |
| Stomach | 2 | 0.26 | 7.57 (0.92-27.3) |
| Thymus | 2 | 0.02 | 114 (13.8-412)* |
| Female, n = 528 | |||
| All malignant neoplasms† | 35 | 22.2 | 1.58 (1.10-2.19)* |
| NHL | 8 | 0.95 | 8.46 (3.65-16.7)* |
| Leukemia | 2 | 0.40 | 5.01 (0.61-18.1) |
| Stomach | 1 | 0.23 | 4.40 (0.11-24.5) |
| Thymus | 0 | 0.01 | 0-303‡ |
| Cancer site . | O . | E . | SIR (95% CI) . |
|---|---|---|---|
| Male, n = 604 | |||
| All malignant neoplasms† | 23 | 14.0 | 1.64 (1.04-2.46)* |
| NHL | 8 | 0.87 | 9.22 (3.98-18.2)* |
| Leukemia | 2 | 0.35 | 5.77 (0.70-20.9) |
| Stomach | 2 | 0.26 | 7.57 (0.92-27.3) |
| Thymus | 2 | 0.02 | 114 (13.8-412)* |
| Female, n = 528 | |||
| All malignant neoplasms† | 35 | 22.2 | 1.58 (1.10-2.19)* |
| NHL | 8 | 0.95 | 8.46 (3.65-16.7)* |
| Leukemia | 2 | 0.40 | 5.01 (0.61-18.1) |
| Stomach | 1 | 0.23 | 4.40 (0.11-24.5) |
| Thymus | 0 | 0.01 | 0-303‡ |
95% CI indicates 95% confidence interval; E, expected number of cases; NHL, non-Hodgkin lymphoma; O, observed number of cases; PID, primary immune deficiency; and SIR, standardized incidence ratio.
Statistical significance.
C00-C96, excluding C44.
One-tail, 97.5% CI instead of 95% CI because of zero observations.